AR029333A1 - Combinacion de drogas no interactivas , formulacion farmaceutica y paquete farmaceutico que comprende dicha combinacion y el uso de un inhibidor de la hmgcoa reductasa en la preparacion de un medicamento que se utiliza en terapia combinada - Google Patents
Combinacion de drogas no interactivas , formulacion farmaceutica y paquete farmaceutico que comprende dicha combinacion y el uso de un inhibidor de la hmgcoa reductasa en la preparacion de un medicamento que se utiliza en terapia combinadaInfo
- Publication number
- AR029333A1 AR029333A1 ARP000100507A ARP000100507A AR029333A1 AR 029333 A1 AR029333 A1 AR 029333A1 AR P000100507 A ARP000100507 A AR P000100507A AR P000100507 A ARP000100507 A AR P000100507A AR 029333 A1 AR029333 A1 AR 029333A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- inhibitor
- preparation
- pharmaceutical
- hmgcoa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Combinaciones de drogas no interactivas seguras de un inhibidor de la 3-hidroxi-3-metilglutaril coenzima A (HMG-CoA) reductasa, que es ácido (E) -7[4- (4-fluorofenil) - 6 isopropil-2-[metil (metilsulfonil) amino] pirimidin-5-il] (3R, 5S) -3,5 dihidroxihept-6 enoico o una sal farmacéuticamente aceptable del mismo (el Agente) y una droga que sea un inductor, inhibidor o sustrato del citocromo P450, en particular la isoenzima 34A del citocromo P450. Formulaciones farmacéuticas y paquetes farmacéuticos que comprenden dichas combinaciones también se describen. El inhibidor de la reductasa, el ácido (E) -7[4- (4-fluorofenil)-6 isopropil-2-[metil (metilsulfonil) amino]pirimidin-5-il] (3R, 5S) -3,5-dihidroxihept-6-enoico o una sal farmacéuticamente aceptable del mismo se usa en la preparacion de un medicamento que se usa en terapia combinada con una segunda droga que es un inductor, inhibidor o sustrato de la isoenzima 34A del citocromo P450. Los medicamentos que comprenden estas combinaciones particulares son utiles en el tratamiento de la hiperlipidemia y de las condiciones cardiovasculares en humanos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9902593.4A GB9902593D0 (en) | 1999-02-06 | 1999-02-06 | Drug combinations |
| GBGB9921064.3A GB9921064D0 (en) | 1999-09-08 | 1999-09-08 | Drug combination |
| GBGB9921063.5A GB9921063D0 (en) | 1999-09-08 | 1999-09-08 | Therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029333A1 true AR029333A1 (es) | 2003-06-25 |
Family
ID=27269637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100507A AR029333A1 (es) | 1999-02-06 | 2000-02-04 | Combinacion de drogas no interactivas , formulacion farmaceutica y paquete farmaceutico que comprende dicha combinacion y el uso de un inhibidor de la hmgcoa reductasa en la preparacion de un medicamento que se utiliza en terapia combinada |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US6982157B1 (es) |
| EP (1) | EP1185274B1 (es) |
| JP (2) | JP2002536331A (es) |
| KR (2) | KR20010101790A (es) |
| CN (1) | CN1165310C (es) |
| AR (1) | AR029333A1 (es) |
| AT (1) | ATE282415T1 (es) |
| AU (1) | AU767304B2 (es) |
| BR (1) | BR0007999A (es) |
| CA (1) | CA2358632C (es) |
| CZ (1) | CZ301296B6 (es) |
| DE (1) | DE60015965T2 (es) |
| EE (1) | EE04929B1 (es) |
| EG (1) | EG23858A (es) |
| ES (1) | ES2232418T3 (es) |
| GB (1) | GB0000710D0 (es) |
| HK (1) | HK1041817A1 (es) |
| ID (1) | ID30485A (es) |
| IL (1) | IL144715A0 (es) |
| IS (1) | IS2337B (es) |
| MX (1) | MXPA01007905A (es) |
| MY (1) | MY130606A (es) |
| NO (1) | NO320745B1 (es) |
| NZ (1) | NZ512982A (es) |
| PL (1) | PL198034B1 (es) |
| PT (1) | PT1185274E (es) |
| TR (1) | TR200102228T2 (es) |
| TW (1) | TWI282738B (es) |
| WO (1) | WO2000045817A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
| US7658944B2 (en) | 2003-10-10 | 2010-02-09 | Lifecycle Pharma A/S | Solid dosage form comprising a fibrate |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| EP1786414A4 (en) | 2004-08-06 | 2008-04-09 | Transform Pharmaceuticals Inc | NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES |
| WO2007005941A2 (en) | 2005-07-05 | 2007-01-11 | President And Fellows Of Harvard College | Liver targeted conjugates |
| CN101330919B (zh) * | 2005-12-20 | 2012-12-05 | 力奇制药公司 | 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物 |
| US20080109252A1 (en) * | 2006-11-08 | 2008-05-08 | Lafountain Andrea | Predicting patient compliance with medical treatment |
| US20120130202A1 (en) * | 2010-11-24 | 2012-05-24 | Fujitsu Limited | Diagnosis and Monitoring of Musculoskeletal Pathologies |
| CA3103616A1 (en) * | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition |
| JP2022542004A (ja) | 2019-07-31 | 2022-09-29 | インタス ファーマシューティカルズ リミテッド | ＨＭＧ－ＣｏＡレダクターゼ阻害剤及びフェノフィブラートを含む医薬組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| DK0521417T3 (da) * | 1991-07-02 | 1995-03-27 | Benckiser Gmbh Joh A | Sammenklappelig forrådsflaske |
| JP3852621B2 (ja) * | 1992-01-21 | 2006-12-06 | あすか製薬株式会社 | 血管内皮細胞機能改善剤 |
| FR2730231B1 (fr) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
| AU1289899A (en) * | 1997-10-31 | 1999-05-24 | Arch Development Corporation | Methods and compositions for regulation of 5-alpha reductase activity |
-
2000
- 2000-01-14 GB GBGB0000710.4A patent/GB0000710D0/en not_active Ceased
- 2000-02-01 ES ES00901264T patent/ES2232418T3/es not_active Expired - Lifetime
- 2000-02-01 CZ CZ20012844A patent/CZ301296B6/cs not_active IP Right Cessation
- 2000-02-01 MX MXPA01007905A patent/MXPA01007905A/es not_active IP Right Cessation
- 2000-02-01 AU AU21218/00A patent/AU767304B2/en not_active Expired
- 2000-02-01 TR TR2001/02228T patent/TR200102228T2/xx unknown
- 2000-02-01 IL IL14471500A patent/IL144715A0/xx not_active IP Right Cessation
- 2000-02-01 WO PCT/GB2000/000278 patent/WO2000045817A1/en not_active Application Discontinuation
- 2000-02-01 PT PT00901264T patent/PT1185274E/pt unknown
- 2000-02-01 CN CNB008034702A patent/CN1165310C/zh not_active Expired - Lifetime
- 2000-02-01 DE DE60015965T patent/DE60015965T2/de not_active Expired - Lifetime
- 2000-02-01 ID IDW00200101892A patent/ID30485A/id unknown
- 2000-02-01 EP EP00901264A patent/EP1185274B1/en not_active Expired - Lifetime
- 2000-02-01 US US09/889,414 patent/US6982157B1/en not_active Expired - Lifetime
- 2000-02-01 NZ NZ512982A patent/NZ512982A/en not_active IP Right Cessation
- 2000-02-01 KR KR1020017009914A patent/KR20010101790A/ko active Search and Examination
- 2000-02-01 KR KR1020067021986A patent/KR20060117381A/ko not_active Application Discontinuation
- 2000-02-01 CA CA002358632A patent/CA2358632C/en not_active Expired - Fee Related
- 2000-02-01 PL PL364780A patent/PL198034B1/pl unknown
- 2000-02-01 EE EEP200100406A patent/EE04929B1/xx unknown
- 2000-02-01 BR BR0007999-5A patent/BR0007999A/pt not_active Application Discontinuation
- 2000-02-01 AT AT00901264T patent/ATE282415T1/de active
- 2000-02-01 JP JP2000596937A patent/JP2002536331A/ja active Pending
- 2000-02-04 MY MYPI20000416A patent/MY130606A/en unknown
- 2000-02-04 AR ARP000100507A patent/AR029333A1/es unknown
- 2000-02-22 EG EG20000124A patent/EG23858A/xx active
- 2000-05-11 TW TW089102105A patent/TWI282738B/zh not_active IP Right Cessation
-
2001
- 2001-07-17 IS IS6009A patent/IS2337B/is unknown
- 2001-08-03 NO NO20013811A patent/NO320745B1/no not_active IP Right Cessation
-
2002
- 2002-05-08 HK HK02103512A patent/HK1041817A1/xx unknown
-
2005
- 2005-03-15 US US11/079,530 patent/US20060040969A1/en not_active Abandoned
-
2007
- 2007-07-27 JP JP2007195798A patent/JP2007277267A/ja active Pending
-
2008
- 2008-09-29 US US12/285,117 patent/US20090042911A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029333A1 (es) | Combinacion de drogas no interactivas , formulacion farmaceutica y paquete farmaceutico que comprende dicha combinacion y el uso de un inhibidor de la hmgcoa reductasa en la preparacion de un medicamento que se utiliza en terapia combinada | |
| AR035500A1 (es) | Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina. | |
| BR0007974A (pt) | Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo | |
| UY26372A1 (es) | "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen " | |
| ATE309798T1 (de) | Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate | |
| DE69805001D1 (de) | Osmotische darreichungsform mit zwei mantelschichten | |
| IE970731A1 (en) | Product and method for the treatment of hyperlipidemia | |
| ATE514424T1 (de) | Pharmazeutische zubereitungen von taxanen | |
| MY118371A (en) | Tetrahydrolipstatin containing compositions | |
| CY1109861T1 (el) | Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης | |
| ATE292453T1 (de) | Antivirale arznei | |
| AU2002214305A1 (en) | Pharmaceutical preparation containing copolyvidone | |
| ATE324886T1 (de) | Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp | |
| WO2005055955A3 (en) | DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY | |
| WO2002007721A3 (en) | Use of cox-2 inhibitors for preventing immunodeficiency | |
| DE60018629D1 (de) | Carbamazepinformulierung mit verzögerter Freigabe | |
| ATE304844T1 (de) | Entzündungshemmende pharmazeutische formulierungen | |
| BR0109747A (pt) | Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática | |
| AR038858A1 (es) | Combinacion | |
| CA2385755A1 (en) | Prevention of colorectal cancer | |
| AR022462A1 (es) | Uso de un agente que disminuye el colesterol | |
| WO2005058310A3 (en) | Use of stating for the treatment of metabolic syndrome | |
| HK1079981A1 (en) | A pharmaceutical preparation comprising a abacavirand alovudine and use thereof | |
| WO2001060326A3 (fr) | Composition cosmetique ou pharmaceutique contenant une lactone sesquiterpenique | |
| ECSP982396A (es) | Composiciones que contienen tetrahidrolipstatina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |